3,4-methylenedioxymethamphetamine (mdma): A review

Current Psychiatry Reports

Volumn 3, Issue 6, 2001, Pages 477-483

  O’Leary, Grace ^a   Nargiso, Jessica ^a   Weiss, Roger D ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

Ecstasy; MDEA; MDMA; Positron Emission Tomography; Single Photon Emission Compute Tomography

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; PSYCHEDELIC AGENT; SEROTONIN RECEPTOR;

ADDICTION; BRAIN; CHEMICALLY INDUCED DISORDER; DEPRESSION; DRUG EFFECT; HUMAN; MALIGNANT HYPERTHERMIA; REVIEW;

BRAIN; DEPRESSION; HALLUCINOGENS; HUMANS; MALIGNANT HYPERTHERMIA; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RECEPTORS, SEROTONIN; SUBSTANCE-RELATED DISORDERS;

EID: 0038407836     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-001-0041-y     Document Type: Review

References (80)

1. Zickler P: Annual Survey Finds Increasing Teen use of Ecstasy, Steroids, 2001. This survey of school age students found that from 1999 to 2000, Ecstasy use increased in eighth-graders and 12th-graders from 1.7% to 3.1% and from 3.6% to 5.6%, respectively. This annual survey examined 45,000 school age students nationwide.
2. Shulgin A: The background and chemistry of MDMA. J Psychoactive Drugs 1986, 18:291–304.
3. Greer G, Strassman R: Information on Ecstasy. Am J Psychiatry 1985, 142:1391.
4. Greer G, Tolbert R: Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 1986, 18:319–327.
5. Nichols D: Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 1986, 18:305–313.
6. Ricaurte G, Bryan G, Strauss L, et al.: Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 1985, 229:986–988. DOI: 10.1126/science.4023719
7. Barnes D: Ecstasy returns to schedule I. Science 1988, 240:24. DOI: 10.1126/science.2895498
8. Randall T: Ecstasy-fueled "rave" parties become dances of death for English youths. Med News Perspect 1992, 268:1505–1506.
9. Millman R, Beeder B: The new psychedelic culture: LSD, Ecstasy, "rave" parties and The Grateful Dead. Psychiatr Ann 1994, 24:148–150.
10. Weir E: Raves: a review of the culture, the drugs and the prevention of harm. CMAJ 2000, 162:1843–1848.
11. Randall T: "Rave" scene, Ecstasy use, leap Atlantic. JAMA 1992, 268:1506. DOI: 10.1001/jama.268.12.1506
12. Peroutka S: Incidence of recreational use of 3,4-methylenedimethoxymethamphetamine (MDMA, "Ecstasy") on an undergraduate campus. N Engl J Med 1987, 317:1542–1543.
13. Riley S, James C, Gregory D, et al.: Patterns of recreational drug use at dance events in Edinburgh, Scotland. Addiction 2001, 96:1035–1047. DOI: 10.1046/j.1360-0443.2001.967103513.x
14. Schuckit M: MDMA (Ecstasy): an old drug with new tricks. Drug Abuse Alcohol Newsletter 1994, 23:1–4.
15. Morgan M: Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology 2000, 152:230–248. DOI: 10.1007/s002130000545
16. Helmlin H-J, Bracher K, Bourquin D, et al.: Analysis of 3, 4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. J Anal Toxicol 1996, 20:432–440.
17. Zhao H, Brenneisen R, Scholer A, et al.: Profiles of urine samples taken from Ecstasy users at rave parties: analysis by immunoassays, HPLC, and GC-MS. J Anal Toxicol 2001, 25:258–269.
18. Pacifici R, Farre M, Pichini S, et al.: Sweat testing of MDMA with the Drugwipe Analytical Device: a controlled study with two volunteers. J Anal Toxicol 2001, 25:144–146. MDMA and its metabolites are not easily detected in human bodily fluids. In this study, immunochemical strips applied to two human subjects between 2 and 12 hours after initial ingestion of MDMA were able to detect MDMA in its metabolites in their sweat, suggesting that the immunochemical strips may be an effective means of rapidly detecting this substance in humans suspected of ingesting MDMA.
19. Battaglia G, Yeh S, O’Hearn E, et al.: 3,4-methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetinelabeled serotonin uptake sites. J Pharmacol Exp Ther 1987, 242:911–916.
20. O’Hearn E, Battaglia G, De Souza E, et al.: Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 1988, 8:2788–2803.
21. Slikker W Jr, Ali S, Scallet A, et al.: Neurochemical and neurohistiological slterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol Appl Pharmacol 1988, 94:448–457. DOI: 10.1016/0041-008X(88)90285-2
22. McCann U, Ridenour A, Shaham Y, Ricaurte G: Serotonin neurotoxicity after (+/-) 3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. Neuropsychopharmacology 1994, 10:129–138.
23. McCann U, Szabo Z, Scheffel U, et al.: Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 1998, 352:1433–1437. DOI: 10.1016/S0140-6736(98)04329-3
24. Stone D, Stahl D, Hanson G, Gibb J: The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3, 4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol 1986, 128:41–48. DOI: 10.1016/0014-2999(86)90555-8
25. Lyon R, Glennon R, Titeler M: 3,4-methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacology 1986, 88:525–526. DOI: 10.1007/BF00178519
26. Steele T, Nichols D, Yim G: Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain. Biochem Pharmacol 1987, 36:2297–2303. DOI: 10.1016/0006-2952(87)90594-6
27. Schmidt C, Taylor V: Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol 1987, 36:4095–4102. DOI: 10.1016/0006-2952(87)90566-1
28. Stone D, Merchant K, Hanson G, Gibb J: Immediate and longterm effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 1987, 26:1677–1683. DOI: 10.1016/0028-3908(87)90117-1
29. Meltzer H, Lowy M: The serotonin hypothesis of depression. In Psychopharmacology: The Third Generation of Progress. Edited by Meltzer H. New York: Raven Press; 1987.
30. Davidson D, Parrott A: Ecstasy (MDMA) in recreational users: self-report psychological and physiological effects. Hum Psychopharmacol 1997, 12:221–226. DOI: 10.1002/(SICI)1099-1077(199705/06)12:3<221::AID-HUP854>3.0.CO;2-C
31. Liester M, Grob C, Bravo G, Walsh R: Phenomenology and sequelae of 3,4-methylenedioxymethampethamine use. J Nerv Ment Dis 1992, 180:345–352. DOI: 10.1097/00005053-199206000-00001
32. Siegel R: MDMA: nonmedical use and intoxication. J Psychoactive Drugs 1986, 18:349–354.
33. Solowij N, Hall W, Lee N: Recreational MDMA use in Sydney: a profile of ‘Ecstasy’ users and their experiences with the drug. Br J Psychiatry 1992, 87:1161–1172.
34. Dowling G, McDouough E, Bost R: "Eve" and "Ecstasy": a report of five deaths associated with the use of MDA and MDMA. JAMA 1987, 257:1615–1617. DOI: 10.1001/jama.257.12.1615
35. Lukaszewski T: 3,4-methylenedioxyamphetamine overdose. Clin Toxicol 1979, 15:405–409.
36. Poklis A, Mackell M, Drake W: Fatal intoxication from 3,4-methylenedioxyamphetamine. J Forensic Sci 1979, 24:70–75.
37. Reed D, Cravey R, Sedgwick P: A fatal case involving methylenedioxyamphetamine. Clin Toxicol 1972, 5:3–6.
38. Campkin N, Davies U: Another death from Ecstasy. J R Soc Med 1992, 85:61.
39. Coore J: A fatal trip with Ecstasy: a case of 3,4-methylenedioxymethamphetamine/ 3,4-methylenedioxyamphetamine toxicity. J R Soc Med 1996, 89:51–52.
40. Maxwell D, Polkey M, Henry J: Hyponatraemia and catatonic stupor after taking Ecstasy. BMJ 1993, 307:1399.
41. Chadwick I, Linsley A, Freemont A, et al.: Ecstasy, 3,4-methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia. J Royal Soc Med 1991, 84:371.
42. Dykhuizen R, Brunt P, Atkinson P, et al.: Ecstasy induced hepatitis mimicking viral hepatitis. Gut 1995, 36:939–941.
43. Fidler H, Dhillon A, Gertner D, Burroughs A: Chronic Ecstasy (3,4-methylenedioxymethamphetamine) abuse: a recurrent and unpredictable cause of severe acute hepatitis. J Hepatol 1996, 25:563–566. DOI: 10.1016/S0168-8278(96)80217-0
44. Khakoo S, Coles C, Armstrong J, Barry R: Hepatotoxicity and accelerated fibrosis following 3,4-methylenedioxymethamphetamine (Ecstasy) usage. J Clin Gastroenterol 1995, 20:244–247. DOI: 10.1097/00004836-199504000-00017
45. Gledhill J, Moore D, Bell D, Henry J: Subarachnoid hemorrhage associated with MDMA abuse. J Neurol Neurosurg Psychiatry 1993, 56:1036–1037.
46. Hanyu A, Ikeguchi K, Imai H, et al.: Cerebral infarction associated with 3,4-methylenedioxymethamphetamine (Ecstasy) abuse. Eur Neurol 1995, 35:173.
47. Duflou J, Mark A: Aortic dissection after ingestion of Ecstasy MDMA. Am J Forensic Med Pathol 2000, 21:261–263. DOI: 10.1097/00000433-200009000-00016
48. Suarez R, Riemersma R: Ecstasy and sudden cardiac death. Am J Forensic Med Pathol 1988, 9:339–341.
49. Coccaro E, Siever L, Klar H, et al.: Serotonergic studies in patients with affective and personality disorders. Arch Gen Psychiatry 1989, 46:587–599.
50. Benazzi F, Mazzoli M: Psychiatric illness associated with Ecstasy. Lancet 1991, 338:1520. DOI: 10.1016/0140-6736(91)92332-V
51. Curran H, Travill R: Mood and cognitive effects of +/− 3,4-methylenedioxymethamphetamine (MDMA; Ecstasy): weekend-end "high" followed by mid-week low. Addiction 1997, 92:821–831. DOI: 10.1111/j.1360-0443.1997.tb02951.x
52. Krystal J: Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function? Am J Drug Alcohol Abuse 1992, 18:331–341.
53. McCann U, Ricaurte G: Lasting neuropsychiatric sequelae of (+/-) methylenedioxymethamphetamine (Ecstasy) in recreational use. J Clin Psychopharmacol 1991, 11:302–305. DOI: 10.1097/00004714-199110000-00005
54. McGuire P, Cope H, Fahy T: Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine (Ecstasy). Br J Psychiatry 1994, 165:391–395.
55. Parrott A, Lasky J: Ecstasy (MDMA) effects on mood and cognition: before, during and after a Saturday night dance. Psychopharmacology 1998, 139:261–268. DOI: 10.1007/s002130050714
56. Schifano F, Di Furia L, Minicuci N, Briolo R: MDMA (Ecstasy) consumption in the context of polydrug use: a report on 150 patients. Drug Alcohol Depend 1998, 52:85–90. DOI: 10.1016/S0376-8716(98)00051-9
57. Cassidy G, Ballard C: Psychiatric sequelae of MDMA (Ecstasy) and related drugs. Ir J Psychol Med 1994, 11:132–133.
58. Creighton F, Black D, Hyde C: Ecstasy psychosis and flashbacks. Br J Psychiatry 1991, 159:713–715.
59. McGuire P, Fahy T: Chronic paranoid psychosis after misuse of MDMA (Ecstasy). BMJ 1991, 302:697.
60. Schifano F: Chronic atypical psychosis associated with MDMA (Ecstasy) abuse. Lancet 1991, 338:1335. DOI: 10.1016/0140-6736(91)92633-D
61. Vaiva G, Boss V, Bailly D, et al.: An "accidental" acute psychosis with Ecstasy use. J Psychoactive Drugs 2001, 33:95–98. This case study presented one individual who experienced an acute episode of psychosis characterized by delusions and violent behavior 12 hours after ingesting MDMA. Although he had no previously known psychiatric history, he met criteria for mild major depression with some psychotic symptoms 6 months after taking MDMA.
62. Parrott A, Sisk E, Turner J: Psychobiological problems in heavy ‘Ecstasy’ (MDMA) polydrug users. Drug Alcohol Depend 2000, 60:105–110. In this study using clinical symptoms self-assessment scales to compare a group of heavy MDMA users with a non-MDMA using control group, heavy users had significantly greater levels of anxiety, paranoid ideation, anorexia, somatization, obsessionality, psychoticism, and disturbed sleep patterns than did controls. Light MDMA users had intermediate symptom on the majority of self-assessment scores when compared with controls except on measures of paranoid ideation and psychoticism. The authors suggest those early indicators (psychoticism and paranoia) of developing psychiatric disorders present in light users may continue with continued MDMA use. DOI: 10.1016/S0376-8716(99)00146-5
63. Pallanti S, Mazzi D: MDMA (Ecstasy) precipitation of panic disorder. Biol Psychiatry 1992, 32:91–95. DOI: 10.1016/0006-3223(92)90145-P
64. Whitaker-Azmitia P, Aronson T: Ecstasy (MDMA)-induced panic. Am J Psychiatry 1989, 146:119.
65. Morgan M: Recreational use of Ecstasy (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology 1998, 19:252–264. A group of 16 MDMA users was compared with 1) a group of 12 non-MDMA users with substance use and personal histories comparable to the MDMA users, and 2) a group of 16 non-substance-using controls. Using the Impulsiveness, Venturesomeness, and Empathy Scale (IVE), a significant difference between the MDMA group and the other groups was seen on measures of impulsiveness but no significant differences were reported on other scale measures. DOI: 10.1016/S0893-133X(98)00012-8
66. Commins D, Vosmer G, Virus R, et al.: Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 1987, 241:338–345.
67. Schmidt C: Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 1987, 240:1–7.
68. Ricaurte G, Forno L, Wilson M, et al.: (+/-) 3,4-methylenedioxymethamphetmine selectively damages central sertonergic neurons in nonhuman primates. JAMA 1988, 260:51–55. DOI: 10.1001/jama.260.1.51
69. Insel T, Battaglia G, Johannessen J, et al.: 3,4-methylenedioxymethamphetamine (Ecstasy) selectively destroys brain serotonin terminals in Rhesus monkeys. J Pharmacol Exp Ther 1989, 249:713–720.
70. Ricaurte G, Martello A, Katz J, Martello M: Lasting effects of (+/-) 3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther 1992, 261:616–622.
71. Peroutka S, Pascoe N, Faull K: Monoamine metabolites in the cerebrospinal fluid of recreational users of 3,4-methylenedioxymethamphetamine. Res Commun Substance Abuse 1987, 8:125–138.
72. Ricaurte G, Finnegan K, Irwin I, Langston J: Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations. Ann N Y Acad Sci 1990, 600:699–710. DOI: 10.1111/j.1749-6632.1990.tb16919.x
73. Price L, Ricaurte G, Krystal J, Heninger G: Neuroendocrineand mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Arch Gen Psychiatry 1989, 46:20–22.
74. Verkes R, Gijsman H, Pieters M, et al.: Cognitive performance and serotonergic function in users of Ecstasy. Psychopharmacology 2001, 153:196–202. DOI: 10.1007/s002130000563
75. Semple D, Ebmeier K, Glabus M, et al.: Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (Ecstasy) users. Br J Psychiatry 1999, 175:63–69. In this study, 10 long-term Ecstasy users and 10 non-Ecstasy using but substance using controls were administered a serotonin transporter ligand before undergoing neuroimaging with single photon emission computed tomography (SPECT). Diminished binding to cortical serotonin transporters was found in long-term Ecstasy users compared with controls that used substances other than Ecstasy.
76. Obrocki J, Buchert R, Vaterlein O, et al.: Ecstasy-long-term effects on the human central nervous system revealed by positron emission tomography. Br J Psychiatry 1999, 175:186–188. This neuroimaging study used positron emission tomography (PET) and 2-[18F]-fluoro-2-deoxy-d-glucose to examine glucose metabolism, an indicator of neuronal activity, in seven Ecstasy users who had not used the substance for 2 to 16 months and seven non-substance using controls. Decreased glucose metabolism in the neurons of the hippocampus, amygdala, and cingulate was seen in the abstinent Ecstasy users compared with the non-substance using controls. DOI: 10.1192/bjp.175.2.186
77. Buchert R, Obrocki J, Thomasius R, et al.: Long-term effects of Ecstasy abuse on the human brain studied by FDG PET. Nucl Med Commun 2001, 22:889–897. In this study using PET, 93 Ecstasy users who had taken approximately 483 Ecstasy tablets for approximately 20 years (last use 6.5 months prior to the study) demonstrated decreased FDG uptake in the striatum, cingulate, amygdala, cortex, and hippocampus, bilaterally when compared with 27 non-substance using controls. Greater reductions in 2-[18F]-fluoro-2-deoxy-d-glucose uptake were seen in those began using Ecstasy before the age of 18. DOI: 10.1097/00006231-200108000-00007
78. Curren H: Is MDMA neurotoxic in humans? An overview of evidence and of methodological problems in research. Neuropsychobiology 2000, 42:34–41. DOI: 10.1159/000026668
79. Baggott M, Heifets B, Jones R, et al.: Chemical analysis of Ecstasy pills. JAMA 2000, 284:2190. In this study 107 Ecstasy tablets were examined for their content by GCMS. MDMA or its analogues, MDEA and MDA, were found in 67 tablets although 31 tablets contained no MDMA, but other identifiable substances including dextromethorphan, caffeine, ephedrine, pseudoephedrine, and salicylates. Nine tablets contained no identifiable drug at all. DOI: 10.1001/jama.284.17.2190
80. Sherlock K, Wolff K, Hay A, Conner M: Analysis of illicit Ecstasy tablets: implications for clinical management in the accident and emergency departments. J Accid Emerg Med 1999, 16:194–197. Twenty-five Ecstasy tablets were analyzed for content by gas chromatography. Of the 25 tablets, 12 tablets contained MDMA, four tablets contained MDEA, and the other 9 contained no MDMA, but instead contained varying amounts of caffeine, amphetamine, ephedrine, ketamine, and paracetamol.